COVID early treatment protocol as well as prevention protocol, and nasal-oral wash povidone iodine is added now; we are ensuring that this nasal-oral wash is part of early treatment as it is near 100%

by Paul Alexander

if only one action you can take, here out, then always use nasal-oral wash, it is that effective; & remember, most built upon Dr. Zev Zelenko's initial 'Zelenko protocol'. Huge thanks to this angel.

In other words, if the only thing you did was the nasal-oral wash a few times a day, at this time as we address BA.5 sub-variant, you will cut the risk of infection etc. by near 100%.


Early treatment:



Povidone-Iodine Use in Sino-nasal and Oral Cavities: A Review of Safety in the COVID-19 Era

Show all authorsSamantha Frank, MD, Joseph Capriotti, MD, Seth M. Brown, MD, MBA, ...

First Published June 10, 2020 Review Article Find in PubMed

Article information 




Approaches to nasal and oral decontamination with povidone-iodine (PVP-I) have been published to reduce nosocomial spread of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2). The safety of PVP-I topically applied to the nasal and oral cavity is addressed by a literature review. The specific efficacy of PVP-I against coronaviruses and its potential efficacy against SARS-CoV-2 is discussed.


A review was performed utilizing PubMed and Cochrane Databases. All citations in protocols for nasal and oral PVP-I use regarding COVID-19 were independently reviewed.


Povidone-iodine has been safely administered for up to 5 months in the nasal cavity and 6 months in the oral cavity. Concentrations less than 2.5% in vitro do not reduce ciliary beat frequency or cause pathological changes in ciliated nasal epithelium, upper respiratory, or mucosal cells. Adverse events with oral use have not been reported in conscious adults or children. Allergy and contact sensitivity is rare. Chronic mucosal use up to 5% has not been shown to result in clinical thyroid disease. PVP-I is rapidly virucidal and inactivates coronaviruses, including SARS-CoV and Middle East Respiratory Syndrome (MERS).


Povidone-iodine can safely be used in the nose at concentrations up to 1.25% and in the mouth at concentrations up to 2.5% for up to 5 months. Povidone-iodine rapidly inactivates coronaviruses, including SARS and MERS, when applied for as little as 15 seconds. There is optimism that PVP-I can inactivate SARS-CoV-2, but in vitro efficacy has not yet been demonstrated.